Yanmei Xu

机构：Chinese Academy of Medical Sciences & Peking Union Medical College, Institute of Hematology & Blood Diseases Hospital · ORCID：0000-0003-4607-9781

发表论文 8 篇 · 总被引 132 次 · h-index 5

代表论文

• A Novel Anti-CD38 Monoclonal Antibody for Treating Immune Thrombocytopenia (2024 · New England Journal of Medicine · 被引 48)
• Efficacy and safety of human umbilical cord-derived mesenchymal stem cells in the treatment of refractory immune thrombocytopenia: a prospective, single arm, phase I trial (2024 · Signal Transduction and Targeted Therapy · 被引 33)
• The Daily Intake Levels of Copper, Selenium, and Zinc Are Associated with Osteoarthritis but Not with Rheumatoid Arthritis in a Cross-sectional Study (2023 · Biological Trace Element Research · 被引 29)
• Global, regional and national burden of rheumatoid arthritis, and attributable risk factors from 1990 to 2019: update from the Global Burden of Disease 2019 study (2022 · Clinical and Experimental Rheumatology · 被引 13)
• Anti-CD38 monoclonal antibody CM313 for primary immune thrombocytopenia: multicentre, randomised, placebo controlled, phase 2 trial (2025 · BMJ · 被引 6)
• The daily intake and serum levels of copper, selenium and zinc are associated with osteoarthritis but not with rheumatoid arthritis in a cross-section study (2023 · Research Square · 被引 2)